KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Accounts Payables: 2009-2024

Historic Accounts Payables for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $88.4 million.

  • Alnylam Pharmaceuticals' Accounts Payables rose 66.08% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year increase of 66.08%. This contributed to the annual value of $88.4 million for FY2024, which is 59.25% up from last year.
  • As of FY2024, Alnylam Pharmaceuticals' Accounts Payables stood at $88.4 million, which was up 59.25% from $55.5 million recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Accounts Payables high stood at $98.1 million for FY2022, and its period low was $52.0 million during FY2020.
  • In the last 3 years, Alnylam Pharmaceuticals' Accounts Payables had a median value of $88.4 million in 2024 and averaged $80.7 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Accounts Payables slumped by 43.40% in 2023 and then spiked by 59.25% in 2024.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Accounts Payables stood at $52.0 million in 2020, then surged by 41.30% to $73.4 million in 2021, then soared by 33.60% to $98.1 million in 2022, then crashed by 43.40% to $55.5 million in 2023, then surged by 59.25% to $88.4 million in 2024.